NanoViricides Inc (NNVC) - Net Assets
Based on the latest financial reports, NanoViricides Inc (NNVC) has net assets worth $7.17 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.36 Million) and total liabilities ($1.18 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of NanoViricides Inc to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.17 Million |
| % of Total Assets | 85.85% |
| Annual Growth Rate | 9.96% |
| 5-Year Change | -74.87% |
| 10-Year Change | -67.38% |
| Growth Volatility | 125.4 |
NanoViricides Inc - Net Assets Trend (2006–2025)
This chart illustrates how NanoViricides Inc's net assets have evolved over time, based on quarterly financial data. Also explore NNVC total assets for the complete picture of this company's asset base.
Annual Net Assets for NanoViricides Inc (2006–2025)
The table below shows the annual net assets of NanoViricides Inc from 2006 to 2025. For live valuation and market cap data, see NNVC company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $7.52 Million | -34.43% |
| 2024-06-30 | $11.46 Million | -22.88% |
| 2023-06-30 | $14.87 Million | -35.60% |
| 2022-06-30 | $23.08 Million | -22.83% |
| 2021-06-30 | $29.91 Million | +37.47% |
| 2020-06-30 | $21.76 Million | +105.26% |
| 2019-06-30 | $10.60 Million | -39.99% |
| 2018-06-30 | $17.66 Million | -13.08% |
| 2017-06-30 | $20.32 Million | -11.83% |
| 2016-06-30 | $23.05 Million | -27.49% |
| 2015-06-30 | $31.79 Million | +11.12% |
| 2014-06-30 | $28.60 Million | +257.13% |
| 2013-06-30 | $8.01 Million | -42.17% |
| 2012-06-30 | $13.85 Million | +36.17% |
| 2011-06-30 | $10.17 Million | +56.03% |
| 2010-06-30 | $6.52 Million | +162.26% |
| 2009-06-30 | $2.49 Million | +460.14% |
| 2008-06-30 | $443.74K | -11.31% |
| 2007-06-30 | $500.34K | -59.60% |
| 2006-06-30 | $1.24 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to NanoViricides Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14867587600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $166.00 | 0.00% |
| Other Components | $156.36 Million | 2079.92% |
| Total Equity | $7.52 Million | 100.00% |
NanoViricides Inc Competitors by Market Cap
The table below lists competitors of NanoViricides Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PlumbFast Co. Ltd
KQ:035200
|
$21.60 Million |
|
Hanchang Ind.Co.Ltd
KQ:079170
|
$21.60 Million |
|
Lottery.com Inc.
NASDAQ:SEGG
|
$21.61 Million |
|
Ken Holdings Bhd
KLSE:7323
|
$21.61 Million |
|
Zungwon En-Sys Inc
KQ:045510
|
$21.57 Million |
|
Invoicery Group AB
ST:FRILAN
|
$21.57 Million |
|
BRAINCOOL AB
F:5YL
|
$21.56 Million |
|
OneSavings Bank PLC
LSE:OSB
|
$21.56 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NanoViricides Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 11,464,077 to 7,517,566, a change of -3,946,511 (-34.4%).
- Net loss of 9,466,966 reduced equity.
- New share issuances of 5,296,429 increased equity.
- Other comprehensive income increased equity by 9.
- Other factors increased equity by 224,017.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-9.47 Million | -125.93% |
| Share Issuances | $5.30 Million | +70.45% |
| Other Comprehensive Income | $9.00 | +0.0% |
| Other Changes | $224.02K | +2.98% |
| Total Change | $- | -34.43% |
Book Value vs Market Value Analysis
This analysis compares NanoViricides Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.12x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-06-30 | $-0.05 | $1.55 | x |
| 2006-06-30 | $0.84 | $1.55 | x |
| 2007-06-30 | $0.31 | $1.55 | x |
| 2008-06-30 | $0.27 | $1.55 | x |
| 2009-06-30 | $1.45 | $1.55 | x |
| 2010-06-30 | $3.50 | $1.55 | x |
| 2011-06-30 | $5.12 | $1.55 | x |
| 2012-06-30 | $6.48 | $1.55 | x |
| 2013-06-30 | $3.36 | $1.55 | x |
| 2014-06-30 | $11.17 | $1.55 | x |
| 2015-06-30 | $10.73 | $1.55 | x |
| 2016-06-30 | $7.99 | $1.55 | x |
| 2017-06-30 | $6.76 | $1.55 | x |
| 2018-06-30 | $5.44 | $1.55 | x |
| 2019-06-30 | $2.95 | $1.55 | x |
| 2020-06-30 | $3.87 | $1.55 | x |
| 2021-06-30 | $2.74 | $1.55 | x |
| 2022-06-30 | $2.00 | $1.55 | x |
| 2023-06-30 | $1.28 | $1.55 | x |
| 2024-06-30 | $0.97 | $1.55 | x |
| 2025-06-30 | $0.50 | $1.55 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NanoViricides Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -125.93%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.17x
- Recent ROE (-125.93%) is below the historical average (-122.48%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $-59.40K |
| 2006 | -265.20% | 0.00% | 0.00x | 2.20x | $-3.41 Million |
| 2007 | -623.37% | 0.00% | 0.00x | 2.70x | $-3.17 Million |
| 2008 | -617.11% | 0.00% | 0.00x | 3.31x | $-2.78 Million |
| 2009 | -112.16% | 0.00% | 0.00x | 1.21x | $-3.04 Million |
| 2010 | -72.78% | 0.00% | 0.00x | 1.38x | $-5.40 Million |
| 2011 | -63.68% | 0.00% | 0.00x | 1.06x | $-7.49 Million |
| 2012 | -44.82% | 0.00% | 0.00x | 1.13x | $-7.59 Million |
| 2013 | -110.81% | 0.00% | 0.00x | 2.05x | $-9.68 Million |
| 2014 | -49.31% | 0.00% | 0.00x | 1.56x | $-16.97 Million |
| 2015 | -6.92% | 0.00% | 0.00x | 1.39x | $-5.38 Million |
| 2016 | -46.53% | 0.00% | 0.00x | 1.59x | $-13.03 Million |
| 2017 | -50.71% | 0.00% | 0.00x | 1.33x | $-12.34 Million |
| 2018 | -48.48% | 0.00% | 0.00x | 1.05x | $-10.33 Million |
| 2019 | -77.78% | 0.00% | 0.00x | 1.27x | $-9.30 Million |
| 2020 | -61.80% | 0.00% | 0.00x | 1.10x | $-15.62 Million |
| 2021 | -29.49% | 0.00% | 0.00x | 1.01x | $-11.81 Million |
| 2022 | -35.12% | 0.00% | 0.00x | 1.02x | $-10.42 Million |
| 2023 | -57.77% | 0.00% | 0.00x | 1.14x | $-10.08 Million |
| 2024 | -72.35% | 0.00% | 0.00x | 1.12x | $-9.44 Million |
| 2025 | -125.93% | 0.00% | 0.00x | 1.17x | $-10.22 Million |
Industry Comparison
This section compares NanoViricides Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $161,374,297
- Average return on equity (ROE) among peers: -386.97%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NanoViricides Inc (NNVC) | $7.17 Million | 0.00% | 0.16x | $21.57 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $98.20 Million |
| Abcellera Biologics Inc (ABCL) | $1.14 Billion | -12.83% | 0.19x | $1.57 Billion |
| Abeona Therapeutics Inc (ABEO) | $681.00K | -3192.95% | 12.43x | $313.99 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $179.85 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $793.56 Million |
| Arbutus Biopharma Corp (ABUS) | $26.88 Million | -30.41% | 0.07x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $-1.46 Million | 0.00% | 0.00x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $84.98 Million | -24.53% | 0.28x | $3.65 Billion |
About NanoViricides Inc
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product for… Read more